Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Wednesday announced that its Board of Directors has unanimously approved that Chief R&D and Commercial Officer Najat Khan will take over from Chris Gibson as Chief Executive Officer and President effective January 1, 2026.
Najat will also continue serving on the Board of Directors.
Gibson will transition to Chairman of the Board and interim Executive Advisor, while current Chairman Rob Hershberg will assume the role of Vice-Chairman and Lead Independent Director.
In the pre-market trading, Recursion Pharma is 1.2000% lesser at $4.9400 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.